People

The power of our transpacific partnerships lies at the heart of our investment and company building strategy. We leverage an extensive global network as well as an &#8220;on-the-ground&#8221;, local presence in both Japan and the United States. This enables us to access differentiated sourcing and early-stage investment opportunities for the creation and development of bespoke new biotech companies on both sides of the Pacific. Through this approach, the team gains insights and perspectives that enable it to maximize therapeutic impact for patients around the world, while generating attractive risk-adjusted returns for investors.

Catalys Pacific maximizes its profound global network and robust local presence in Japan to propel its mission of improving patient lives. It is an honor to be a part of that mission.”

Transforming Life Sciences Innovation By Creating And Investing In Global Companies

Catalys Pacific

Home

IPO Archives - Catalys Pacific

Dr. Tachi Yamada

Chairman and Co-founder of Phathom Pharmaceuticals

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the clinical drug candidate vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.

Going Beyond to Advance Treatments for Patients with Acid-Related Disorders

Phathom Pharmaceuticals - Catalys Pacific

Phathom Pharmaceuticals

Acquired

Acquired Archives - Catalys Pacific

Jean-Guillaume Lecomte

CEO Bioprojet

Aculys Pharma is a private biopharmaceutical company focused on the development and commercialization of innovations in the therapeutic area of CNS for the greater Japan region. It was founded by Catalys Pacific to address the increasing “drug lag” for innovative new medicines that fail to reach patients in the region. Licensed in from Bioprojet Pharma (Paris, France), Aculys’ lead asset, pitolisant, is a best-in-class treatment approved for Narcolepsy Type 1 (including cataplexy) in the US and EU and recently approved for Obstructive Sleep Apnea as well in the EU.

Tackling the Social Issues in Neurology Head-on

Home

Creations

Phathom Pharmaceuticals

Aculys